myeloid cells

[Diabetologia] The authors investigated whether fenofibrate increased circulating hematopoietic stem/progenitor cells (HSPCs). When compared with placebo, fenofibrate significantly increased levels of HSPCs expressing CD34 and/or CD133.

[Advanced Science] Transcriptomic analysis showed that IFN-γ and IFN-α signaling was downregulated in IRF8-deficient HSCs, while their response to proinflammatory cytokines was unchanged ex vivo.

[Trillium Therapeutics, Inc.] Trillium Therapeutics, Inc. announced that it has dosed the first TP53-mutated acute myeloid leukemia patient with TTI-622, an investigational checkpoint inhibitor of the innate immune system, in combination with azacitidine.

[Scientific Reports] Scientists investigated the cellular response of different antigen presenting cells to the prototypical immunogenic heat shock protein, gp96, in the context of Th1 immunity.

[Nature Communications] Researchers showed that FcγR-mediated endocytosis of antibody-antigen complexes or an anti-FcγRIIIB-antigen conjugate converted neutrophils into neutrophil-derived cells with properties of dendritic cells (DCs) that activate T cells to levels observed with classical DCs.

[Cancer Discovery] The authors found that SHP2 inhibitor treatment depleted alveolar and M2-like macrophages, induced tumor-intrinsic CCL5/CXCL10 secretion and promoted B and T lymphocyte infiltration in Kras- and Egfr-mutant non-small cell lung cancer.